Drug Profile

Baclofen oral - Saol Therapeutics

Alternative Names: Baclofen oral granules; LYVISPAH

Latest Information Update: 06 Jun 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Saol Therapeutics
Class Aminobutyric acids; Antispastics; Muscle relaxants; Small molecules
Mechanism of Action GABA receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Substance-related disorders
New Molecular Entity No

Highest Development Phases

Marketed Muscle spasticity

Most Recent Events

01 Jun 2022 Launched for Muscle spasticity (In adolescents, In adults) in USA (PO)
05 Jan 2022 Amneal Pharmaceuticals acquires baclofen oral from Saol Therapeutics
07 Dec 2021 Saol Therapeutics plans to launch baclofen oral (LYVISPAH™) (In adolescents, In adults) in 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com